What is Aurobindo Pharma Ltd's PE ratio?

Aurobindo Pharma Ltd trades at a P/E ratio of 25.20.

What is Aurobindo Pharma Ltd's market cap?

Aurobindo Pharma Ltd's market capitalisation is ₹95,116 Cr.

When did Aurobindo Pharma Ltd last report results?

Aurobindo Pharma Ltd last reported Q1FY27 results on 5 Aug '26.

What is Aurobindo Pharma Ltd's ROE?

Aurobindo Pharma Ltd's return on equity (ROE) is 10.1%.

What sector is Aurobindo Pharma Ltd in?

Aurobindo Pharma Ltd (AUROPHARMA) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Aurobindo Pharma Ltd (AUROPHARMA)

₹1,658.40

Mkt cap

₹95,116 Cr

P/E ratio

25.20

P/B

2.54

Div yield

0.24%

ROE

10.10%

ROCE

12.90%

EPS (TTM)

₹65.81

Book value

₹652

52W range

1,022–1,717

Sector

Healthcare

Price history

Previous close

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

NSE AUROPHARMABSE 524804

Health check

Constructive

ValuationCheap

ProfitabilityAverage

GrowthModerate

TechnicalsBullish

52-week range

−3.41% from high

₹1,658

₹1,022+62.24% from low₹1,717

Current

₹1,658.40

Prev close

₹1,653.10

Day

+0.32%

Price performance

+0.32%

−3.41%

+0.02%

+14.45%

+38.73%

+61.80%

YTD

+36.45%

Financials

Revenue, profit & margin

P/E ratio

25.2×

AUROPHARMA is 26% below the sector median of 34.0×

AUROPHARMA25.2×

Sector median34.0×

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	6,851	7,219	7,352	7,580	7,567	7,796	7,979	8,382	7,868	8,286	8,646	8,853	9,150
Expenses	5,702	5,846	5,753	5,920	5,949	6,230	6,401	6,622	6,265	6,608	6,873	7,103	7,271
Operating Profit	1,149	1,373	1,599	1,660	1,618	1,566	1,578	1,760	1,603	1,678	1,773	1,750	1,880
OPM %	17%	19%	22%	22%	21%	20%	20%	21%	20%	20%	21%	20%	21%
Other Income	47	188	163	14	221	136	159	135	107	122	123	117	224
Interest	57	68	76	89	111	113	118	115	98	95	93	98	102
Depreciation	327	418	423	354	404	382	419	444	406	429	465	479	487
Profit before tax	812	1,076	1,262	1,230	1,324	1,207	1,200	1,335	1,207	1,276	1,339	1,291	1,515
Tax %	30%	30%	26%	26%	31%	32%	30%	32%	32%	34%	32%	29%	32%
Net Profit	570	752	940	907	918	817	846	903	824	848	910	921	1,032
EPS in Rs	9.74	12.92	15.98	15.51	15.69	14.07	14.56	15.56	14.20	14.61	15.67	15.86	17.95
Raw PDF

Earnings

Results dates & reactions

No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.06% · closed higher next day 29 of last 61

	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Broadcast	10 Nov '23	10 Feb '24◦	25 May '24◦	10 Aug '24◦	9 Nov '24◦	6 Feb '25◦	27 May '25	4 Aug '25◦	5 Nov '25◦	9 Feb '26◦	21 May '26◦	5 Aug '26◦
Earnings day	+3.04%	+1.55%	−3.13%	+0.83%	−2.90%	−0.01%	+0.87%	−1.02%	−0.74%	−6.61%	−5.38%	−1.52%
+1 day	+3.03%	+2.32%	−1.14%	+3.87%	−4.53%	−1.23%	−2.80%	−1.66%	−2.20%	−4.74%	−5.95%	+2.76%
+5 days	+4.98%	+3.76%	−0.62%	+6.04%	−5.83%	−5.07%	−3.14%	−2.95%	+5.32%	−1.41%	−7.31%	+3.10%
+15 days	+7.91%	+8.75%	+0.62%	+6.88%	−5.13%	−10.85%	−6.03%	−5.88%	+7.55%	−0.69%	−8.95%	+1.46%
+30 days	+12.50%	+6.70%	+7.88%	+3.55%	−5.37%	+0.26%	−2.81%	+3.53%	+5.24%	+8.65%	+2.35%	—
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	XBRL	XBRL	XBRL	XBRL

Corporate actions

Last 6 months

Kind	Value	Ex-date	Record
other Buy Back	—	17 Apr '26	17 Apr '26

Results analysis

Shareholding

as of Jun 2026

51.88%Promoter

Promoters51.88%0.06

FIIs16.38%1.14

DIIs25.05%0.77

Public6.63%0.45

Government0.05%

Ownership trend

Peers

8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
SUNPHARMA	₹1,899.00	36.07	4,55,634	0.84%	2,901	+5.95%	15,300	+10.46%	20.53%
DIVISLAB	₹9,100.00	81.09	2,41,576	0.33%	902	+65.50%	3,080	+27.80%	21.97%
TORNTPHARM	₹4,857.00	82.80	1,84,745	0.78%	566	+5.79%	4,921	+54.85%	15.19%
CIPLA	₹1,385.00	31.26	1,11,888	0.94%	786	−39.19%	7,119	+2.33%	15.49%
ZYDUSLIFE	₹1,120.00	22.95	1,11,720	0.09%	990	−35.09%	8,017	+21.96%	21.14%
LAURUSLABS	₹1,840.00	90.93	99,417	0.11%	362	+125.49%	2,026	+29.10%	17.76%
LUPIN	₹2,110.00	16.20	96,483	0.85%	1,417	+16.08%	8,277	+32.04%	29.93%
AUROPHARMA	₹1,653.10	25.16	95,116	0.24%	1,032	+28.11%	9,150	+16.30%	12.86%
Median: 158 Co.	₹421.50	33.96	2,277	0.08%	13	+30.25%	164	+18.67%	14.96%

Filings

Annual reports15

Annual Report 2026bse Annual Report 2025bse Annual Report 2024bse Annual Report 2023bse Annual Report 2022bse Annual Report 2021bse Annual Report 2020bse Annual Report 2019bse Annual Report 2018bse Annual Report 2017bse Annual Report 2016bse Annual Report 2015bse Annual Report 2014bse Annual Report 2013bse Annual Report 2013nse

Credit ratings6

Rating update 10 Junfitch Rating update 11 Mar 2025fitch Rating update 20 Dec 2023fitch Rating update 20 Oct 2022fitch Rating update 6 Aug 2021fitch Rating update 4 Aug 2021fitch

Announcements5

Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Submission of notice published in newspapers.Announcement under Regulation 30 (LODR)-Acquisition 1 Sep - Apitoria Pharma incorporated Avogent Lifesciences Private Limited in India on August 31, 2026, with Rs.5 crore capital.Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 31 Aug - Lannett launches generic Advair Diskus in the US, first inhalation product commercialized.Completion Of US FDA Inspection At Unit-VI Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company 28 Aug - US FDA inspected Apitoria Pharma's Unit-VI from Aug 24-28, 2026; concluded with three procedural observations.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 28 Aug